Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03410693 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Transitional Cell

Interventions

DRUG: Rogaratinib (BAY1163877)
DRUG: Chemotherapy

Sponsor

Bayer